Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | PNMT | P11086 | 8/20 | 0.48 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29956163 | 0.98 | ASIC3 (0.53) | ASIC3DRD2DRD3PLAUPNMT | |
| Bromide SCHEMBL2553326 | 0.98 | ASIC3 (0.53) | ASIC3DRD2DRD3PLAUPNMT | |
| SCHEMBL30688443 | 0.93 | PNMT (0.55) | DRD2DRD3PNMTADRA2AADRA2B | |
| SCHEMBL15331124 | 0.93 | PNMT (0.55) | DRD2DRD3PNMTADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL29955415 | 0.91 | PNMT (0.53) | DRD2DRD3PNMTADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL28685881 | 0.91 | PNMT (0.53) | DRD2DRD3PNMTADRA2AADRA2B | |
| SCHEMBL12672783 | 0.84 | CYP2A6 (0.42) | PLAU | |
| SCHEMBL30956943 | 0.84 | CYP2A6 (0.42) | PLAU | |
| Hydrochloric Acid SCHEMBL28927078 | 0.82 | CYP2A6 (0.41) | PLAU | |
| SCHEMBL25405565 | 0.81 | ASIC3 (0.55) | ASIC3DRD2DRD3PLAUPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260180-B | Triazole condensed ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| WO-2024047227-A1 | SORTILIN MODULATORS | INSUSENSE ApS (DK) | 2024-03-07 | — | — | WO | disclosed |
| CN-115260180-A | Triazole fused ring containing derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-106661034-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2019-11-29 | — | — | CN | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| CN-106661034-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | AUSPEX PHARMACEUTICALS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| CN-103079558-A | IRE-1 alpha inhibitors | MANNKIND CORP | 2013-05-01 | — | — | CN | disclosed |
| WO-2009020457-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| EP-1366036-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | Allergan, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2002018361-A2 | COMPOUNDS HAVING ACTIVITY AS INHIBITORS OF CYTOCHROME P450RAI | ALLERGAN, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078270-A1 | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI | CYP26B1, CYP21A2, ALDH1A2 | ASIC3 4700/4885DRD2 4525/4885DRD3 4186/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ASIC3 3129/4885DRD2 2415/4885DRD3 2263/4885 |
| US-20150080426-A1 | BENZOQUINOLINE INHIBITORS OF VMAT 2 | SLC18A2, ACAT2, SLC6A2 | ASIC3 2190/4885DRD2 1650/4885DRD3 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.